Metabolic Dysfunction Associated Fatty Liver Disease in Long-Term Cholecystectomy Patients

NACompletedINTERVENTIONAL
Enrollment

149

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2024

Conditions
Liver Steatoses
Interventions
DIAGNOSTIC_TEST

USG, blood tests, waist, hip, height and blood pressure measurements

"MAFLD is defined as hepatic steatosis entity in addition to the presence of overweight or obesity, DM, or evidence of metabolic dysfunction.~Metabolic dysfunction (two or more of the following)~1. waist circumference ≥ 90 cm in men and 88 cm in women,~2. blood pressure ≥ 130/85 mmHg or on specific drug treatment,~3. plasma triglycerides (TG) ≥ 150 mg/dl or on specific drug treatment,~4. plasma high-density lipoprotein cholesterol (HDL-C) \< 40 mg/dl for men and 50 mg/dl for women or on specific drug treatment,~5. prediabetes (FBS 100 to 125 mg/dl or HbA1c 5.7 to 6.4%),~6. homeostasis model assessment of insulin resistance (HOMA-IR) score ≥ 2.5."

Trial Locations (1)

Unknown

Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara

All Listed Sponsors
lead

Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital

OTHER

NCT06443723 - Metabolic Dysfunction Associated Fatty Liver Disease in Long-Term Cholecystectomy Patients | Biotech Hunter | Biotech Hunter